According to Takeda Pharmaceutical's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.41977. At the end of 2023 the company had a P/S ratio of 1.54.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.54 | -6.32% |
2022 | 1.64 | 18.76% |
2021 | 1.38 | -26.85% |
2020 | 1.89 | -9.59% |
2019 | 2.09 | 28.42% |
2018 | 1.62 | -41.66% |
2017 | 2.78 | 36.85% |
2016 | 2.04 | -22.01% |
2015 | 2.61 | 27.24% |
2014 | 2.05 | -5.8% |
2013 | 2.18 | 18.42% |
2012 | 1.84 | -2.25% |
2011 | 1.88 | -19.67% |
2010 | 2.34 | 12.02% |
2009 | 2.09 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.75 | 164.15% | ๐บ๐ธ USA |
Novartis NVS | 3.73 | 162.71% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.46 | 73.31% | ๐บ๐ธ USA |
Amgen AMGN | 5.02 | 253.59% | ๐บ๐ธ USA |
Sanofi SNY | 2.32 | 63.54% | ๐ซ๐ท France |
Merck MRK | 5.28 | 272.08% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.19 | 54.36% | ๐ฌ๐ง UK |
Seagen
SGEN | 18.8 | 1,221.35% | ๐บ๐ธ USA |
Dr. Reddy's RDY | 3.66 | 157.82% | ๐ฎ๐ณ India |